The BRITISH Study (led by Dr Andrew Flett of University Hospitals Southampton) has recently been awarded £1.8m from the BHF. The study aims to determine whether heart muscle scar predicts high risk in dilated cardiomyopathy and therefore the use of implantable cardioverter defibrillators (ICD). The trial (1252 patients, 35 UK centres) will analyse Cardiac MRI scans and randomize those with scar to ICD or not, seeing if the ICD improves patient outcomes. It is powered to inform national and international guidelines and thereby global patient care. Both those with and without scar will be uploaded to a corelab.
Mycardium AI will conduct the analysis of the CMR Images using innovative AI technology developed at University College London. “The AI developed by Dr Rhodri Davies and now deployed through Mycardium AI, a UCL spin-out, is 40% more precise than expert human analysis. This means that treatment effects can be detected faster, more cost effectively and enables subgroups to be tested”, said Prof James Moon (CEO Mycardium AI), “We look forward to supporting Dr Andrew Flett and the team at UHS in delivering this vital study.”
Dr Andrew Flett PI of BRITISH said “It’s important that the results of our trial are based upon the most accurate of measurements if we are to improve patient care and save lives, using the Mycardium Core Lab services, allows us to do that whilst also utilizing centralized image analysis services to streamline the delivery of BRITISH”